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Abstract: Background: Disordered thyroid hormone transport, due to mutations in the SLC16A2 gene
encoding monocarboxylate transporter 8 (MCT8), is characterised by intellectual and motor disability
resulting from cerebral hypothyroidism and chronic peripheral thyrotoxicosis. We sought to systematically
assess the phenotypic characteristics and natural history of patients with MCT8 deficiency. Methods:
We did an international, multicentre, cohort study, analysing retrospective data from Jan 1, 2003, to Dec
31, 2019, from patients with MCT8 deficiency followed up in 47 hospitals in 22 countries globally. The
key inclusion criterion was genetically confirmed MCT8 deficiency. There were no exclusion criteria. Our
primary objective was to analyse the overall survival of patients with MCT8 deficiency and document
causes of death. We also compared survival between patients who did or did not attain full head control
by age 1·5 years and between patients who were or were not underweight by age 1-3 years (defined as a
bodyweight-for-age Z score <-2 SDs or <5th percentile according to WHO definition). Other objectives
were to assess neurocognitive function and outcomes, and clinical parameters including anthropometric
characteristics, biochemical markers, and neuroimaging findings. Findings: Between Oct 14, 2014, and
Jan 17, 2020, we enrolled 151 patients with 73 different MCT8 (SLC16A2) mutations. Median age at
diagnosis was 24·0 months (IQR 12·0-60·0, range 0·0-744·0). 32 (21%) of 151 patients died; the
main causes of mortality in these patients were pulmonary infection (six [19%]) and sudden death (six
[19%]). Median overall survival was 35·0 years (95% CI 8·3-61·7). Individuals who did not attain
head control by age 1·5 years had an increased risk of death compared with patients who did attain
head control (hazard ratio [HR] 3·46, 95% CI 1·76-8·34; log-rank test p=0·0041). Patients who were
underweight during age 1-3 years had an increased risk for death compared with patients who were of
normal bodyweight at this age (HR 4·71, 95% CI 1·26-17·58, p=0·021). The few motor and cognitive
abilities of patients did not improve with age, as evidenced by the absence of significant correlations
between biological age and scores on the Gross Motor Function Measure-88 and Bayley Scales of Infant
Development III. Tri-iodothyronine concentrations were above the age-specific upper limit in 96 (95%) of
101 patients and free thyroxine concentrations were below the age-specific lower limit in 94 (89%) of 106
patients. 59 (71%) of 83 patients were underweight. 25 (53%) of 47 patients had elevated systolic blood
pressure above the 90th percentile, 34 (76%) of 45 patients had premature atrial contractions, and 20
(31%) of 64 had resting tachycardia. The most consistent MRI finding was a global delay in myelination,
which occurred in 13 (100%) of 13 patients. Interpretation: Our description of characteristics of MCT8
deficiency in a large patient cohort reveals poor survival with a high prevalence of treatable underlying
risk factors, and provides knowledge that might inform clinical management and future evaluation of
therapies. Funding: Netherlands Organisation for Health Research and Development, and the Sherman
Foundation.
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Abstract: Background:  Disordered thyroid hormone transport, due to mutations in
monocarboxylate transporter 8 (MCT8; gene:  SLC16A2  ), is characterized by
intellectual and motor disability due to cerebral hypothyroidism and chronic peripheral
thyrotoxicosis. Phenotypic characteristics and natural history of MCT8 deficiency have
not been systematically evaluated.
Methods:  In this international, multicentre, study, retrospective data (2003 to 2019)
from patients with MCT8 deficiency followed in 47 centres, was analysed. Our primary
objectives were to determine neurocognitive outcomes and overall survival. We also
assessed clinical parameters, including anthropometric characteristics, biochemical
markers and neuroimaging findings.
Results:  151 subjects with 73 different MCT8 (  SLC16A2  ) mutations were included.
21·2% (32/151) of patients died, with main causes of mortality in these patients being
pulmonary infection (18·8%) and sudden death (18·8%). The median overall survival
was 35·0 (95%CI 8·3-61·7) years. Survival differed significantly between individuals
who attained head control by the age of 1·5 years or not (log-rank test: p=0·0041;
hazard ratio 3·46 95%CI 1·76-8·34). Patients who were underweight during early
childhood (1-3 years of age) had an increased risk for death compared with patients
who were not underweight at this age (HR 4·71, 95% CI 1·26-17·58, p=0·021).  The
limited motor and cognitive abilities of patients did not improve with age. T3
concentrations were elevated in 95·1% (96/101) and total T4 concentrations were
reduced in 89·5% (94/105) of patients. 71·1% (59/83) patients were underweight (<-
2SD). Cardiovascular abnormalities were frequent, with 53·2% (25/47) of patients
exhibiting elevated systolic blood pressure, and 75·6% (34/45) of patients having
premature atrial contractions and 31·3% (20/60) having resting tachycardia.
Interpretation  Our description of characteristics of MCT8 deficiency in a large patient
cohort reveals poor survival with a high prevalence of treatable underlying risk factors
and provides knowledge which informs clinical management and future evaluation of
therapies.  
Funding  Our study was funded by the Netherlands Organisation for Health Research
and Development (project number 113303005; to WEV), and the Sherman Foundation
(to WEV).
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Background: Disordered thyroid hormone transport, due to mutations in monocarboxylate 2 
transporter 8 (MCT8; gene: SLC16A2), is characterized by intellectual and motor disability due 3 
to cerebral hypothyroidism and chronic peripheral thyrotoxicosis. Phenotypic characteristics 4 
and natural history of MCT8 deficiency have not been systematically evaluated. 5 
Methods: In this international, multicentre, study, retrospective data (2003 to 2019) from 6 
patients with MCT8 deficiency followed in 47 centres, was analysed. Our primary objectives 7 
were to determine neurocognitive outcomes and overall survival. We also assessed clinical 8 
parameters, including anthropometric characteristics, biochemical markers and neuroimaging 9 
findings. 10 
Results: 151 subjects with 73 different MCT8 (SLC16A2) mutations were included. 21·2% 11 
(32/151) of patients died, with main causes of mortality in these patients being pulmonary 12 
infection (18·8%) and sudden death (18·8%). The median overall survival was 35·0 (95%CI 8·3-13 
61·7) years. Survival differed significantly between individuals who attained head control by 14 
the age of 1·5 years or not (log-rank test: p=0·0041; hazard ratio 3·46 95%CI 1·76-8·34). 15 
Patients who were underweight during early childhood (1-3 years of age) had an increased 16 
risk for death compared with patients who were not underweight at this age (HR 4·71, 95% CI 17 
1·26-17·58, p=0·021).  The limited motor and cognitive abilities of patients did not improve 18 
with age. T3 concentrations were elevated in 95·1% (96/101) and total T4 concentrations were 19 
reduced in 89·5% (94/105) of patients. 71·1% (59/83) patients were underweight (<-2SD). 20 
Cardiovascular abnormalities were frequent, with 53·2% (25/47) of patients exhibiting 21 
elevated systolic blood pressure, and 75·6% (34/45) of patients having premature atrial 22 
contractions and 31·3% (20/60) having resting tachycardia.  23 
6 
 
Interpretation Our description of characteristics of MCT8 deficiency in a large patient cohort 24 
reveals poor survival with a high prevalence of treatable underlying risk factors and provides 25 
knowledge which informs clinical management and future evaluation of therapies.   26 
Funding Our study was funded by the Netherlands Organisation for Health Research and 27 
Development (project number 113303005; to WEV), and the Sherman Foundation (to WEV). 28 
  29 
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Research in context 30 
 31 
Evidence before this study 32 
Monocarboxylate transporter 8 (MCT8) deficiency is a rare genetic disorder with devastating 33 
consequences including intellectual and motor disability due to cerebral hypothyroidism and 34 
severe clinical sequelae secondary to chronic peripheral thyrotoxicosis. We searched Pubmed 35 
for studies published in English to January 1, 2020, using the search terms “MCT8 deficiency”, 36 
“Allan-Herndon-Dudley Syndrome”, “AHDS”, “natural history” and “life expectancy”. Prior to 37 
this study, given the rarity of the disorder, knowledge on the phenotypic characteristics, 38 
natural history and life expectancy of monocarboxylate transporter 8 (MCT8) deficiency was 39 
limited. Previous studies consisted of case reports, had small patient cohorts (<25 patients), 40 
and neglected the peripheral features of the disorder. Comprehensive and structured in-depth 41 
characterisation of the phenotype of MCT8 deficiency is urgently needed to accelerate early 42 
diagnosis and inform management, including the use of a new disease-modifying therapy.  43 
 44 
Added value of this study 45 
151 patients from 47 centres across the world were included in the largest study on MCT8 46 
deficiency, to our knowledge. This is the first multicentre, international study to provide in-47 
depth quantitative data on the natural history and life expectancy of patients with MCT8 48 
deficiency. Our data report poor survival in this disorder, with 30% of patients dying in 49 
childhood. Having identified pulmonary infection and sudden death (our data suggests cardiac 50 
arrhythmia as underlying basis) as the major causes of mortality, timely intervention with Triac 51 
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therapy may ameliorate the poor prognosis in this disease. Also, the identification of 52 
underweight being strongly linked to survival provides a direct target for clinical management. 53 
Our detailed description of key clinical features together with biochemical and radiological 54 
correlates constitutes a signature for the disorder which may facilitate its early diagnosis and 55 
discrimination of this entity from other developmental disorders. Our data will be used as 56 
natural history control data for an ongoing trial of with Triac in young children with MCT8 57 
deficiency (NCT02396459). These data will also be important for future clinical trials 58 
investigating treatment options for MCT8 deficiency, such as gene therapy.  59 
 60 
Implications of all the available evidence 61 
Systemic in-depth description of international natural history data will inform clinical 62 
management of patients with MCT8 deficiency. Our findings underscore the need for a 63 
multidisciplinary approach in the management and follow-up of patients with MCT8 64 
deficiency. The current data indicate a unique combination of clinical presentation, 65 
biochemical markers and brain imaging features that will enhance  early diagnosis. The low T4 66 
concentrations measured in the neonatal screening indicates that current neonatal screening 67 
strategy holds potential to detect MCT8 deficiency. These observations hinting at the 68 
possibility of early diagnosis are particularly relevant in the context of Triac therapy recently 69 
reported, which has the potential to ameliorate the devastating course of the disorder if left 70 
untreated. In addition, robust natural history data can be used as controls in clinical trials for 71 





Thyroid hormones are crucial for normal physiological processes, particularly 75 
neurodevelopment, and regulation of basal metabolic rate, throughout life (1, 2). Intracellular 76 
bioavailability of thyroid hormones is governed by membrane transporter proteins that 77 
facilitate their cellular entry (3).  Monocarboxylate transporter 8 (MCT8) is a specific thyroid 78 
hormone transporter that is crucial for transport of triiodothyronine (T3) and thyroxine (T4) 79 
in several tissues, including the brain (4-8). Mutations in the gene encoding MCT8 (SLC16A2 80 
on chromosome Xq13.2) cause MCT8 deficiency, also known as Allan-Herndon-Dudley 81 
syndrome (AHDS), a debilitating disorder with an estimated prevalence of 1 in 70 000 male 82 
individuals (9-11).  83 
MCT8 deficiency is characterized by profound neurodevelopmental delay and a wide 84 
range of severe clinical sequelae secondary to chronic peripheral thyrotoxicosis which cannot 85 
be effectively treated with conventional (anti)thyroid drugs (3, 10, 11).  In 2019, a clinical trial 86 
showed that treatment with triiodothyroacetic acid (Triac) ameliorates key features of 87 
peripheral thyrotoxicosis and might improve neurocognitive outcomes if treatment is 88 
commenced early in life (12).  89 
Robust, comprehensive data regarding the phenotypic characteristics and natural 90 
history of patients with MCT8 deficiency are lacking, as the phenotype has only been recorded 91 
in single case reports or small case series with related patients [e.g. (13, 14)]. Furthermore, 92 
these reports used differing clinical methods precluding consistent assessments, and merely 93 
focused on the neurological phenotype, neglecting the peripheral clinical features of the 94 
disorder (3, 14). Data on survival and neurodevelopmental outcomes in this disorder are not 95 
known. The lack of consistent quantitative knowledge of the natural history and the 96 
10 
 
phenotypic spectrum of MCT8 deficiency hampers early diagnosis and uniform clinical 97 
management including the evaluation of a disease-modifying therapy.  98 
Given the paucity of recorded data and with access to a large patient cohort via an 99 
international collaborative network for this rare disorder, we have sought to provide 100 
comprehensive and uniform phenotypic characterization of MCT8 deficiency using clinical, 101 
radiological, and biochemical data.  102 
Methods 103 
Study design and participants 104 
This international study was initiated on 14 October 2014 by founding a consortium of 105 
centres where patients with MCT8 deficiency were followed before and after this date.  106 
 The key inclusion criterion was genetically confirmed MCT8 deficiency. Additionally, 107 
data on first-degree and second-degree male relatives with clinical MCT8 deficiency (when 108 
genetic testing was not available at that time) were included. There were no exclusion criteria. 109 
Our cohort consisted of patients, evaluated with a standardized protocol,  who had been 110 
enrolled in the international, multicentre Triac Trial [NCT02060474, (12)] and patients who 111 
participated in the named patient program for Triac treatment and historical cases for whom 112 
Erasmus MC fulfilled a consultancy role following the first reports of MCT8 deficiency in 2004 113 
(10, 11) (figure s1).  The group of historical cases therefore contain patients who were alive 114 
and patients who were already deceased at time of enrollment. A subgroup of participants 115 
has been reported before with available individual case descriptions (n=47), or has been 116 
reported on aggregated level (n=46, (12)) (figure s2). For such patients, updated and 117 
exhaustive data were collected.  For analysis of serum thyroid function tests, only patients 118 
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whose measurements were performed in the central laboratory of the Erasmus MC were 119 
considered to avoid inter-assay variation. For in-depth clinical and biochemical phenotyping 120 
only those patients were enrolled that either participated in the Triac Trial (12) or in the 121 
named patient program to ensure data had been captured by trained personnel and according 122 
to standard operating procedures. 123 
Ethical considerations 124 
This study conforms to the Declaration of Helsinki, Good Clinical Practice guidelines 125 
and was evaluated and approved by the appropriate local institutional review boards or ethics 126 
committees. However, for the retrospective analysis of existing datasets of patients in routine 127 
clinical care, the majority of centres did not require additional specific institutional review 128 
board approval. For other centres, studies were either ethically approved or the ethics 129 
committee provided a waiver for approval. Informed consent was obtained from the parents 130 
or legal representatives of all enrolled patients, unless the relevant institutional review board 131 
and/or local regulations had authorized the use of anonymised patient data without additional 132 
consent.  133 
Procedures 134 
An overview of study assessments and investigations is provided in figure s1 and in the 135 
Supplementary Methods.  136 
Outcomes 137 
Our primary objective was to analyse the overall survival of patients with MCT8 138 
deficiency and document causes of death. We also compared survival between patients who 139 
12 
 
did or did not attain full head control by the age of 1·5 years and between patients who were 140 
or were not already underweight by early childhood (between 1-3 years of age).  141 
Other key objectives were to document neurocognitive function using uniform criteria 142 
and assess their relationship to biological age as a measure of disease progression and 143 
developmental outcome and to describe the occurrence of extra-neurological features.  144 
Statistical analysis 145 
We summarised continuous variables as mean and standard deviation (SD), or median 146 
and range. We established overall survival and compared patients with and without full head 147 
control and cases who were or were not underweight during early childhood with log-rank 148 
analysis. Survival was defined as the age at last date known alive. Hazard ratios were 149 
calculated using Cox regression models. Correlations between biological age and scores on 150 
different neuropsychological assessments were explored using linear regression. For these 151 
analyses, we excluded patients with a less severe neurocognitive phenotype, defined as 152 
individuals that attained at least two of the following developmental milestones: talking in 153 
simple words, achieving head control, sitting independently, and/or walking with assistance. 154 
Higher developmental attainment in these patients is more likely to be due to the milder 155 
impact of the underlying MCT8 mutation than to the effect of aging. Assumptions for linear 156 
regression analyses were met. All statistical tests were two-sided, and p values of less than 157 
0·05 were considered statistically significant. Statistical analyses were performed using 158 
GraphPad Prism, version 6 (GraphPad, La Jolla, CA, USA).  159 
Role of funding source 160 
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The funder of the study had no role in study design, data collection, data analysis, data 161 
interpretation, or writing of the report. The corresponding author had full access to all the 162 
data in the study and final responsibility for the decision to submit for publication. 163 
Results 164 
In 47 centres, 151 patients of 22 different nationalities (8 ethnicities) were enrolled 165 
between October 14th 2014 and January 17th 2020 (figure s1), thereby including 50 percent of 166 
families reported thus far (figure s2). In 106 cases serum thyroid function tests had been 167 
measured in the central laboratory, and 86 had been checked according to standardised 168 
protocols for in-depth phenotyping at a median age of 4·8 years (interquartile range [IQR] 1·9-169 
9·8, range 0·4-66·8) (figure s1).  170 
The demographics and characteristics of the enrolled patients are summarised in table 171 
s1. In the 151 enrolled cases, 73 different underlying MCT8 mutations were identified, of 172 
which 36 had not been reported before (figure s3). A total of 17 mutations were identified in 173 
at least two unrelated families. All 35 missense mutations were located in the transmembrane 174 
helices (figure s4). The median age at diagnosis was 24·0 months (range: 0·0-744·0) (figure 175 
1A), but the median age at onset of first symptoms was 4·0 months (range: 0·0-13·0) (figure 176 
1A). Consequently, the median time to diagnosis was 18·0 months (IQR 7·8-63·0, range 0·0-177 
738·0). The most frequently reported initial concerns that prompted medical evaluation were 178 
gross developmental delay (78·6%), hypotonia (39·8%), feeding problems (8·2%), and poor 179 
weight gain (7·1%) (figure 1B).  180 
32 (21·2%) patients had died and the median age of their demise was 10·5 years (IQR 181 
5·3-18·8, range 1·6-71·0). The main causes of death reported for these patients were 182 
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pulmonary infections (18·8%), sudden death (18·8%), and aspiration pneumonia (9·4%) (figure 183 
1C). In 15 (46·9 %) of 32 deceased subjects the cause of death was unclear and postmortem 184 
examinations had not been performed. The median overall survival was 35·0 years (95% CI 185 
8·3-61·7; figure 1D).  The 10-, 18-, and 60-year survival probabilities were 85% (95% CI 78·0-186 
92·0), 69·8% (58·2-80·3), and 34·8% (10·2-59·3), respectively. Patients not attaining full head 187 
control by the age of 1·5 years had an increased risk for death compared with patients who 188 
did attain head control (HR 3·46, 95% CI 1·76-8·34, p=0·0041; figure 1E). Patients who were 189 
underweight during early childhood (1-3 years of age) had an increased risk for death 190 
compared with patients who had a normal body weight by this age (HR 4·71, 95% CI 1·26-191 
17·58, p=0·021, figure 1F). 192 
The prevalence of specific neurological features in patients included in the in-depth 193 
phenotyped cohort (N=86, median age 4·8 years, IQR 1·9-9·8, range 0·4-66·8) is reported in 194 
table 1 and figure 2, and neurological sequelae are summarized in figure s5 and figure s6. All 195 
patients had moderate-to-severe intellectual disability with a severe delay in motor and 196 
language development (table s2). Only 6 (7·7%) patients achieved independent sitting and 197 
were less severely affected than the other patients (figure 2A). The median score on the Gross 198 
Motor Function Measure (GMFM)-88 (15) did not exceed 10% of the total score that should 199 
be obtained by healthy 4-year old children (figure 2B, table s2). Among 28 subjects that had 200 
been evaluated at a median age of 6·4 years (range 0·4-44·6) with the Bayley Scales of Infant 201 
Development (BSID)-III (16), the median developmental age was well-below 12 months on all 202 
tested sub-domains (figure 2C-G, figure s7B-F, table s2). Similar findings were obtained with 203 
the Vineland Adaptive Behavior Scale (VABS)-II (figure s8, table s2). The scores in any of the 204 
developmental domains did not correlate positively with age (e.g. motor skills: GMFM-88 B=-205 
0·10 (95% CI, -0·29-0·09; p=0.29), BSID-III fine motor skills B= -0·11 (-0·23 - 0·01; p=0.072), and 206 
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BSID-III gross motor skills B= -0·04(-0·11- 0·02; p=0.17); figure 2C-G) and scores of patients 207 
with different age categories were not different (table s2)). 208 
Pregnancy and delivery were unremarkable in the majority of cases, with most infants 209 
having normal birth weight and head circumference (table 1). At first presentation, most 210 
patients had global hypotonia with a pronounced head-lag on vertical suspension and upper 211 
trunk slipping through. Typically, by the end of the first year, dystonic posturing of the limbs 212 
and neck were noted. Exaggerated deep tendon reflexes were present in 80·3% (57/71) of 213 
cases, and 90·5% (67/74) of patients developed hypertonia in wrists, knees or heels with age 214 
attributed to dystonia and spasticity. Primitive reflexes remained present in 91·1% (51/56) 215 
cases, with a positive tonic neck reflex (81·0%) and glabellar sign (80·0%) being most prevalent, 216 
irrespective of patient age. Electro-encephalogram (EEG)-confirmed seizures were observed 217 
in 15 (23·1%) of 65 patients, and mostly involved generalized, absence-like episodes without 218 
a clear motor component.  219 
MRI scans of the brain were available in 13 patients, performed at a median age of 8·0 220 
months (range: 5·0-187·0), with 8 patients having at least one follow-up scan available (table 221 
1, figure s5, table s3). The most consistent finding was a global delay in myelination, evidenced 222 
by diffuse residual hyperintense white matter in specific brain regions on T2-weighted images. 223 
Myelination improved with age, but had not fully normalized in the oldest patient (15 years) 224 
with available data. The neuroradiological findings were supported by postmortem findings 225 
(see supplementary results).  226 
 Serum thyroid function tests were available in 106 treatment-naïve patients at a 227 
median age of 5·3 years (IQR 2·1-11·0, range 0·4-66·8). Serum TSH concentrations were within 228 
the normal range in 93 (88·6 %) of 105 patients (figure 3A). Serum free and total T4 229 
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concentrations were below the age-specific lower limit in 94 (88·7 %) of 106 and 94 (89·5%) 230 
of 105 patients, respectively (figure 3B and figure s9A). Mean serum T3 concentrations 231 
exceeded the age-specific upper limit in 96 (95·1%) of 101 patients (figure 3C), which resulted 232 
in a pronounced increase in the T3/T4 ratio (figure s9B). Reverse T3 (rT3) concentrations were 233 
decreased in 76 (90·5%) of 84 patients (figure s9C), with a concomitant increase in the T3/rT3 234 
ratio (figure s9D). This endocrine signature was present regardless of age (figure s9E-H). In 3 235 
out of 7 subjects TRH-stimulation tests showed an inadequate TSH response. In 7 (87·5%) out 236 
of 8 subjects in whom T4-based neonatal screening results were available, total T4 237 
concentrations were below the 20th percentile (figure 3D), and in 5 out of 8 (60%) below the 238 
10th percentile. By contrast, neonatal TSH concentrations were <15 mU/L in 8/8 (100%) of 239 
patients with available data (figure s9I). Serum total T4 concentrations were significantly less 240 
reduced in patients with less severe versus those with a severe neurocognitive phenotype 241 
(1·05±0·22 vs 0·71±0·18 times the age-specific lower limit of normal, p<0·0001) (figure s10A). 242 
Serum T3 concentrations were not significantly different between these groups (1·46±0·23 vs 243 
1·51±0·44 times the age-specific upper limit of normal, p=0·76)(figure s10B). Consequently, 244 
the T3/T4 ratio, a marker of thyroid hormone metabolism in peripheral tissues, was 245 
significantly lower in patients with a less severe phenotype (1·44±0·40 vs 2·27±0·91 times the 246 
age-specific upper limit of normal, p=0·019)  (figure s10C). 247 
 The main findings of in-depth phenotyping of peripheral clinical features (n=86) are 248 
summarised in table 2 and table s4. Body weight for age showed progressive deterioration 249 
over time, with 59 (71·1%) of 83 patients being severely underweight (<-2SD) (figure 3E, table 250 
2). 27 (35·5%) of 76 patients were tube fed, although impaired swallowing function was 251 
reported in 55 (71·4%) of 77 patients. Body height for age also deteriorated with age (figure 252 
3F). Delayed sexual maturation was present in 5 (26·3%) patients (figure s11A-D). Among 253 
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patients over 8 years of age, bone mineral density (BMD) was below the 5th percentile, but 254 
bone turnover markers were generally within the low-normal range (figure s12A-D). 255 
The mean resting heart rate was 110 (±20)  beats per minute, with 20 (31·3%) of 64 256 
patients exceeding the 90th percentile for age (figure 3G) (17). Systolic blood pressure 257 
exceeded the 90th percentile in 25 (53·2%) of 47 patients whereas the diastolic blood pressure 258 
exceeded the 90th percentile in 17 (36·2%) of 47 patients (figure 3H) (18, 19). Detailed 259 
cardiovascular assessment was available in 50 patients. At the time of evaluation, 47 (94%) of 260 
50 patients reportedly had no cardiovascular abnormalities and were not receiving any 261 
treatment. 3 (6·0%) of 50 patients had second-degree atrioventricular block (Mobitz I: 1; 262 
Mobitz II: 2) and 6 (12·0%) of 50 patients had (incomplete) right bundle branch block. In 263 
addition, corrected QT interval (QTc) was above the 98th percentile in three out of 39 (7·7%) 264 
patients (table 2, figure s13A). Even though most patients were completely immobile, 24h 265 
ambulatory cardiac monitoring showed a high resting heart rate (103±13 beats per minute) 266 
with frequent episodes of tachycardia and premature atrial or ventricular contractions (figure 267 
3I, table s4). One childhood patient had an episode of atrial fibrillation and another had non-268 
sustained ventricular tachycardia (table 2). Cardiac echocardiography studies performed in 26 269 
patients revealed dilated aortic root (>+2SD for age, range 2·0-3·4 SD) in 7 (26·9%) patients, 270 
and relatively small left ventricular wall dimensions (figure s13B).  271 
Serum concentrations of sex hormone binding globulin were elevated in 69 (88·5%) of 272 
78 patients (figure 3J, figure s14). Serum alanine aminotransferase, aspartate 273 
aminotransferase, and gamma-glutamyl transferase concentrations were mildly elevated in a 274 
substantial proportion of patients (table 2, figure s15D-F), and two patients reportedly had an 275 
episode of hepatic dysfunction following a (viral) infection.  276 
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43 (84·3%) of 51 patients had low muscle mass. Creatinine concentrations in serum 277 
were within the low-normal range for age (figure 3K, s14B). Serum creatine kinase 278 
concentrations were mostly low-normal (figure 3L, s14C), with some exceptions in patients 279 
with recent seizures or severe dystonic episodes. Other biochemical tests are shown in table 280 
s4 and figure s15A-O.  281 
Gastroesophageal reflux disease was present in 79·2% (38/48) of patients and this 282 
often required pharmacological intervention. Spontaneous gastrointestinal bleeding was 283 
reported in 2 patients and was the cause of death in one of them. Constipation was present 284 
in 62·3% (37/63) of patients. 29 (69·1%) of 42 patients had recurrent (pulmonary) infections 285 
(table 2). 286 
Discussion 287 
To our knowledge, this international, multicentre, retrospective study reports the 288 
quantitative evaluation of the disease characteristics of MCT8 deficiency, in the largest cohort 289 
of patients with this disorder. We have documented key clinical features together with 290 
biochemical and radiological correlates as well as outcomes in this rare but potentially 291 
treatable condition. Our findings will facilitate accurate diagnosis, guide management, and 292 
inform conduct of future therapeutic intervention trials.  293 
A principal finding is that overall survival of patients with MCT8 deficiency is greatly 294 
diminished, with an overall median life expectancy of 35 years. Stratification of analyses 295 
revealed that patients who attain full head control are more likely to survive longer than those 296 
who do not. Accordingly, attaining full head control, as a marker of improved 297 
19 
 
neurodevelopment, could be a relevant endpoint for future therapeutic trials in MCT8 298 
deficiency.  299 
The most common cause of death was pneumonia, caused either by aspiration or by 300 
infections. Aspiration, due to impaired swallowing function, is frequently observed in patients 301 
with MCT8 deficiency, and could be mitigated by tube feeding. However, a substantial number 302 
of patients that exhibited swallowing problems were not tube fed and thus remained at risk 303 
for aspiration. With our study suggesting that being underweight is strongly linked to reduced 304 
survival, tube feeding can prevent adverse clinical sequelae and potentially improve life 305 
expectancy (20). The second major cause of mortality was sudden death. Although its 306 
aetiology remains unclear, available data may suggest a cardiac cause, with the high 307 
prevalence of premature atrial and ventricular contractions, which are uncommon in healthy 308 
individuals especially in childhood (21-25). We also observed non-sustained ventricular 309 
tachycardia and QTc prolongation in some patients, with both considered risk factors for 310 
sudden cardiac death. Moreover, a substantial proportion of patients exhibited systolic 311 
hypertension and/or tachycardia and had several echocardiographic and electrophysiological 312 
cardiac changes that have been linked to these traits. As the vast majority (94·0%) of patients 313 
reportedly had no history of cardiac problems, these cardiovascular abnormalities likely 314 
remain clinically undiagnosed in this population. This observation calls for inclusion of 315 
cardiovascular assessment in the management of this disorder. With loss of body weight and 316 
many cardiovascular abnormalities being attributable to chronic thyrotoxicosis, reduction in 317 
circulating T3 concentrations in patients could represent effective treatment for these aspects 318 
of the disorder. Indeed, in a recent clinical trial, treatment with the thyroid hormone analogue 319 
Triac efficiently reduced serum T3 concentrations and improved key clinical features such as 320 
20 
 
loss of body weight and reversal of abnormal cardiovascular parameters in MCT8 deficiency 321 
(12).  322 
The current study also identified several other clinical features that require treatment 323 
or close follow-up, of which gastro-esophageal reflux disease, scoliosis, hip luxation, and 324 
constipation have the highest prevalence. The presence of mildly elevated aminotransferases 325 
and the occurrence of transient hepatic failure in at least three reported cases following a viral 326 
infection [this report and (11)], suggests that drugs with hepatotoxic side effects (e.g. anti-327 
epileptic drugs as frequently used in this population) should be used with extra caution. 328 
Our comprehensive documentation of neurological sequelae in patients with MCT8 329 
deficiency revealed that the combination of global hypotonia, hypertonia due to dystonia and 330 
spasticity and persistence of primitive reflexes was present in up to 90% of patients. Delayed 331 
myelination on MRI was consistent with other studies (14, 26, 27). Taken together, these 332 
clinical and neuroimaging characteristics may facilitate early diagnosis of MCT8 deficiency and 333 
in discriminating this entity from other neurodevelopmental disorders.  334 
Our study highlights major delay in diagnosis of this disorder, with a minority of cases 335 
being identified in the first year of life. This is mainly attributable to the non-specific initial 336 
clinical features with lack of awareness of the specific characteristics of this disorder among 337 
clinicians. Having documented that circulating T3 concentrations are elevated in patients 338 
below one year of age, the combination of clinical and radiological features with measurement 339 
of serum T3 concentrations may constitute a key clue for early diagnosis. The low T4 340 
concentrations measured in patients with MCT8 deficiency in the neonatal screening indicates 341 
the potential to diagnose MCT8 deficiency in newborns. This may engender debate on 342 
whether modification of the current neonatal screening strategy is warranted. The importance 343 
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of early diagnosis is supported by preclinical studies in which Triac completely prevented 344 
abnormal neurological development in animal models of MCT8 deficiency when administrated 345 
at birth (28). A future phase 2 clinical trial will investigate the effects of Triac on 346 
neurodevelopment, with treatment being commenced at a very young age (NCT02396459).  347 
This study has limitations inherent to its retrospective design. In general, such study 348 
design is prone to collection of an incomplete dataset, possibly resulting in selection bias. 349 
Indeed, most assessments could not be carried out in all patients, resulting in missing data. 350 
The cause of this mostly reflected disease characteristics, such as a poor clinical condition of 351 
patients, their inability to follow instructions and dystonic posturing that hampered 352 
investigations for which patients needed proper positioning. Therefore, some conclusions are 353 
based on a limited number of observations. Yet, calculated prevalence rates for many clinical 354 
features were similar to those observed in smaller cohort studies and through analysis of 355 
existing literature (14). It was also not possible to obtain uniform long-term follow-up data. 356 
However, MCT8 deficiency is a rare disorder with surviving patients being located throughout 357 
the world such that retrospective analysis of available clinical data was the most suitable way 358 
of increasing our understanding of this disorder. In the majority of cases data had been 359 
collected uniformly during baseline assessment of patients whether participating in the Triac 360 
Trial or in named patient treatment programs, providing an unique opportunity for systematic 361 
cross-sectional evaluation of key clinical outcomes. Should MCT8 deficiency result in an 362 
increased rate of miscarriage this will likely remain unascertained, resulting in survivor bias.  363 
Although selection bias cannot be excluded, probably because not all newly diagnosed cases 364 
are brought to our attention and patients who die before the diagnosis has been established 365 
are being missed, our study included a substantial proportion of currently diagnosed patients. 366 
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With advent of Triac as possible disease-modifying therapy, a future, prospective cohort study 367 
of the natural history of the disorder is unlikely to be possible. 368 
In summary, this study provides a comprehensive and structured in-depth 369 
characterisation of the phenotype of MCT8 deficiency. The current study first reports poor 370 
survival in this disorder, with 30% of patients dying in childhood. Having identified pulmonary 371 
infection and sudden death (our data suggests cardiac arrhythmia as underlying basis) as the 372 
major causes of mortality, timely intervention with Triac therapy may ameliorate the poor 373 
prognosis in this disease. Furthermore, our finding that survival is particularly poor in patients 374 
with impaired neurological development (head control) or who are underweight, provides a 375 
basis for therapeutic intervention targeted at this subgroup. Our findings underscore the need 376 
for a multidisciplinary approach in the management and follow-up of patients with MCT8 377 
deficiency. In addition, our observations represent an unique, quantitative dataset of the 378 
characteristics of this disorder which may serve as a historical control for future interventional 379 
studies in this rare disorder, for which a biological control group is often deemed not feasible. 380 
Accordingly, we suggest that this study enhances our understanding of the clinical sequelae 381 
and longterm outcome of MCT8 deficiency and also facilitates the diagnosis and management 382 
of this disorder. 383 
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Legends to the Figures 508 
Figure 1 – Panel A graphically presents the mean ± SEM (black lines) age at onset of symptoms 509 
and the age at time of diagnosis. Grey dots represent measurements in individual patients. 510 
Panel B shows the most commonly reported features that prompted parents to seek medical 511 
attention. Panel C shows the causes of death in patient with MCT8 deficiency based on the 512 
available information derived from the 32 patients in our cohort who died at a median age of 513 
10·5 years (IQR 5·3-18·8, range 1·6-71·0). HR: hazard ratio, calculated using Cox regression 514 
models. Panel D shows the overall survival based on age at last follow-up (Kaplan-Meier 515 
estimates). Panel E shows the Kaplan-Meier estimates of MCT8-specific survival in patients 516 
who attained head control (red line) by the age of 1·5 years versus those who did not (blue 517 
line) and panel F those in patients with underweight (blue line) versus normal body weight 518 
(red line) in early childhood (1-3 years of age). Underweight was defined as a body weight for 519 
age z score <-2SDs (or below the fifth percentile), following the definition of the World Health 520 
Organization. Please note, since potential confounding factors could not be accounted for, a 521 
causal relationship on survival cannot be inferred from the applied stratification variables. 522 
Figure 2 – Panel A shows the prevalence of clinical, radiological and developmental key 523 
features in MCT8 deficiency. Bars indicate the proportion of patients presenting the indicated 524 
feature at first presentation. Panel B represents the gross motor function development in 525 
patients with MCT8 deficiency measured by the Gross Motor Function Measure (GMFM)-88 526 
(15). A 100% score indicates the level of development that is achieved by a healthy 4-year old 527 
child. Panel C shows cognition, panel D receptive language, panel E expressive language, panel 528 
F fine motor skills and panel G gross motor skills, measured by the respective sub-domains of 529 
the Bayley Scales of Infant Development (BSID)-III (16). Scores are expressed as developmental 530 
age in months. In panels B-G, the left figures indicate measurements in individual patients 531 
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(blue dots) and black lines indicate the median score and IQR from all patients with available 532 
data. The right figures show the relation between the neurodevelopmental scores versus the 533 
chronological age using linear regression. A few, predominantly older patients , with an 534 
unexpectedly less severe neurocognitive phenotype (defined as having at least 2 of the 535 
following abilities: talk in simple words, attain head control, independent sitting, and/or 536 
walking with assistance) were excluded from the regression analysis (n=4 for GMFM-88 in 537 
panel B, and n=1 for BSID-III in panel C-G), which focused on individuals with classical sequelae 538 
of severe MCT8 deficiency (indicated with grey dashed lines in the left figure of each panel; 539 
n=40 for GMFM-88 in panel A, and n=27 for BSID-III in panel C-G). Linear regression was used 540 
to plot the trend (blue solid lines) and the 95% confidence intervals (blue dotted lines). Besides 541 
age, no other factors were considered in the models. Patients harboring the same genetic 542 
mutation are displayed in the same color: p.F230del (green), c.651-652+20del (blue), G564R 543 
(purple), p.V566X (pink), and R271H (orange). Unique mutations are colored in grey. 544 
Figure 3 – Mean ± SEM (black lines) serum concentrations of thyroid stimulating hormone 545 
(TSH) (n=106) (panel A) and free T4 (n=106) (panel B). Blue dots represent measurements in 546 
individual patients and grey areas the normal range. Panel C presents the serum total T3 547 
concentrations versus age (n=101). Panel D shows the available results on total T4 548 
measurements during neonatal screening expressed in SDs (n=8). See figure s9I for TSH 549 
measurements during neonatal screening. Panel E shows the natural course of bodyweight 550 
change in patients with MCT8 deficiency. Blue dots represent available historical bodyweight 551 
measurements (n=300) in 86 untreated patients. Non-linear (third order) polynomial 552 
regression was used to plot the trend with its 95% error band. Similarly, panel F shows the 553 
natural course of body height. Accurate measurement of body height can be hampered by 554 
muscle contractions and involuntary movements. Panel G shows the resting heart rate by age 555 
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(n=64). Normal range in healthy children is derived from (17). Panel H shows the mean ± SEM 556 
diastolic and systolic blood pressure (n=47). The orange line represents the threshold for 557 
classification as elevated blood pressure and the red line the threshold of hypertension, as 558 
defined by the guidelines from the American Academy of Pediatrics (18) and the American 559 
College of Cardiology and American Heart Association (19). Panel I shows the mean ± SEM 560 
(black lines) occurrence of indicated features during 24h cardiac monitoring in 45 individuals. 561 
Serum concentration of sex hormone binding globulin (SHBG) (n=78) (panel J), creatinine 562 
(n=79) (panel K), and creatine kinase (n=79) (panel L) are expressed relative to the age-specific 563 
lower (panel K) or upper (panel J and L) limit of the normal range. Abbreviations: TSH, thyroid 564 
stimulating hormone; T4, thyroxine; T3, triiodothyronine; PACs, premature atrial contractions; 565 
PVCs premature ventricular contractions; CK, creatine kinase; SHBG, sex hormone binding 566 
globulin; LL, lower limit; UL, upper limit. The absolute mean values of all parameters are 567 
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Background: Disordered thyroid hormone transport, due to mutations in monocarboxylate 2 
transporter 8 (MCT8; gene: SLC16A2), is characterized by intellectual and motor disability due 3 
to cerebral hypothyroidism and chronic peripheral thyrotoxicosis. Phenotypic characteristics 4 
and natural history of MCT8 deficiency have not been systematically evaluated. 5 
Methods: In this international, multicentre, study, retrospective data (2003 to 2019) from 6 
patients with MCT8 deficiency followed in 47 centres, was analysed. Our primary objectives 7 
were to determine neurocognitive outcomes and overall survival. We also assessed clinical 8 
parameters, including anthropometric characteristics, biochemical markers and neuroimaging 9 
findings. 10 
Results: 151 subjects with 73 different MCT8 (SLC16A2) mutations were included. 21·2% 11 
(32/151) of patients died, with main causes of mortality in these patients being pulmonary 12 
infection (18·8%) and sudden death (18·8%). The median overall survival was 35·0 (95%CI 8·3-13 
61·7) years. Survival differed significantly between individuals who attained head control by 14 
the age of 1·5 years or not (log-rank test: p=0·0041; hazard ratio 3·46 95%CI 1·76-8·34). 15 
Patients who were underweight during early childhood (1-3 years of age) had an increased 16 
risk for death compared with patients who were not underweight at this age (HR 4·71, 95% CI 17 
1·26-17·58, p=0·021).  The limited motor and cognitive abilities of patients did not improve 18 
with age. T3 concentrations were elevated in 95·1% (96/101) and total T4 concentrations were 19 
reduced in 89·5% (94/105) of patients. 71·1% (59/83) patients were underweight (<-2SD). 20 
Cardiovascular abnormalities were frequent, with 53·2% (25/47) of patients exhibiting 21 
elevated systolic blood pressure, and 75·6% (34/45) of patients having premature atrial 22 
contractions and 31·3% (20/60) having resting tachycardia.  23 
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Interpretation Our description of characteristics of MCT8 deficiency in a large patient cohort 24 
reveals poor survival with a high prevalence of treatable underlying risk factors and provides 25 
knowledge which informs clinical management and future evaluation of therapies.   26 
Funding Our study was funded by the Netherlands Organisation for Health Research and 27 
Development (project number 113303005; to WEV), and the Sherman Foundation (to WEV). 28 
  29 
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Research in context 30 
 31 
Evidence before this study 32 
Monocarboxylate transporter 8 (MCT8) deficiency is a rare genetic disorder with devastating 33 
consequences including intellectual and motor disability due to cerebral hypothyroidism and 34 
severe clinical sequelae secondary to chronic peripheral thyrotoxicosis. We searched Pubmed 35 
for studies published in English to January 1, 2020, using the search terms “MCT8 deficiency”, 36 
“Allan-Herndon-Dudley Syndrome”, “AHDS”, “natural history” and “life expectancy”. Prior to 37 
this study, given the rarity of the disorder, knowledge on the phenotypic characteristics, 38 
natural history and life expectancy of monocarboxylate transporter 8 (MCT8) deficiency was 39 
limited. Previous studies consisted of case reports, had small patient cohorts (<25 patients), 40 
and neglected the peripheral features of the disorder. Comprehensive and structured in-depth 41 
characterisation of the phenotype of MCT8 deficiency is urgently needed to accelerate early 42 
diagnosis and inform management, including the use of a new disease-modifying therapy.  43 
 44 
Added value of this study 45 
151 patients from 47 centres across the world were included in the largest study on MCT8 46 
deficiency, to our knowledge. This is the first multicentre, international study to provide in-47 
depth quantitative data on the natural history and life expectancy of patients with MCT8 48 
deficiency. Our data report poor survival in this disorder, with 30% of patients dying in 49 
childhood. Having identified pulmonary infection and sudden death (our data suggests cardiac 50 
arrhythmia as underlying basis) as the major causes of mortality, timely intervention with Triac 51 
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therapy may ameliorate the poor prognosis in this disease. Also, the identification of 52 
underweight being strongly linked to survival provides a direct target for clinical management. 53 
Our detailed description of key clinical features together with biochemical and radiological 54 
correlates constitutes a signature for the disorder which may facilitate its early diagnosis and 55 
discrimination of this entity from other developmental disorders. Our data will be used as 56 
natural history control data for an ongoing trial of with Triac in young children with MCT8 57 
deficiency (NCT02396459). These data will also be important for future clinical trials 58 
investigating treatment options for MCT8 deficiency, such as gene therapy.  59 
 60 
Implications of all the available evidence 61 
Systemic in-depth description of international natural history data will inform clinical 62 
management of patients with MCT8 deficiency. Our findings underscore the need for a 63 
multidisciplinary approach in the management and follow-up of patients with MCT8 64 
deficiency. The current data indicate a unique combination of clinical presentation, 65 
biochemical markers and brain imaging features that will enhance  early diagnosis. The low T4 66 
concentrations measured in the neonatal screening indicates that current neonatal screening 67 
strategy holds potential to detect MCT8 deficiency. These observations hinting at the 68 
possibility of early diagnosis are particularly relevant in the context of Triac therapy recently 69 
reported, which has the potential to ameliorate the devastating course of the disorder if left 70 
untreated. In addition, robust natural history data can be used as controls in clinical trials for 71 
rare diseases in which accrual of placebo controls in group might not be feasible.  72 
 73 
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Thyroid hormones are crucial for normal physiological processes, particularly 75 
neurodevelopment, and regulation of basal metabolic rate, throughout life (1, 2). Intracellular 76 
bioavailability of thyroid hormones is governed by membrane transporter proteins that 77 
facilitate their cellular entry (3).  Monocarboxylate transporter 8 (MCT8) is a specific thyroid 78 
hormone transporter that is crucial for transport of triiodothyronine (T3) and thyroxine (T4) 79 
in several tissues, including the brain (4-8). Mutations in the gene encoding MCT8 (SLC16A2 80 
on chromosome Xq13.2) cause MCT8 deficiency, also known as Allan-Herndon-Dudley 81 
syndrome (AHDS), a debilitating disorder with an estimated prevalence of 1 in 70 000 male 82 
individuals (9-11).  83 
MCT8 deficiency is characterized by profound neurodevelopmental delay and a wide 84 
range of severe clinical sequelae secondary to chronic peripheral thyrotoxicosis which cannot 85 
be effectively treated with conventional (anti)thyroid drugs (3, 10, 11).  In 2019, a clinical trial 86 
showed that treatment with triiodothyroacetic acid (Triac) ameliorates key features of 87 
peripheral thyrotoxicosis and might improve neurocognitive outcomes if treatment is 88 
commenced early in life (12).  89 
Robust, comprehensive data regarding the phenotypic characteristics and natural 90 
history of patients with MCT8 deficiency are lacking, as the phenotype has only been recorded 91 
in single case reports or small case series with related patients [e.g. (13, 14)]. Furthermore, 92 
these reports used differing clinical methods precluding consistent assessments, and merely 93 
focused on the neurological phenotype, neglecting the peripheral clinical features of the 94 
disorder (3, 14). Data on survival and neurodevelopmental outcomes in this disorder are not 95 
known. The lack of consistent quantitative knowledge of the natural history and the 96 
10 
 
phenotypic spectrum of MCT8 deficiency hampers early diagnosis and uniform clinical 97 
management including the evaluation of a disease-modifying therapy.  98 
Given the paucity of recorded data and with access to a large patient cohort via an 99 
international collaborative network for this rare disorder, we have sought to provide 100 
comprehensive and uniform phenotypic characterization of MCT8 deficiency using clinical, 101 
radiological, and biochemical data.  102 
Methods 103 
Study design and participants 104 
This international study was initiated on 14 October 2014 by founding a consortium of 105 
centres where patients with MCT8 deficiency were followed before and after this date.  106 
 The key inclusion criterion was genetically confirmed MCT8 deficiency. Additionally, 107 
data on first-degree and second-degree male relatives with clinical MCT8 deficiency (when 108 
genetic testing was not available at that time) were included. There were no exclusion criteria. 109 
Our cohort consisted of patients, evaluated with a standardized protocol,  who had been 110 
enrolled in the international, multicentre Triac Trial [NCT02060474, (12)] and patients who 111 
participated in the named patient program for Triac treatment and historical cases for whom 112 
Erasmus MC fulfilled a consultancy role following the first reports of MCT8 deficiency in 2004 113 
(10, 11) (figure s1).  The group of historical cases therefore contain patients who were alive 114 
and patients who were already deceased at time of enrollment. A subgroup of participants 115 
has been reported before with available individual case descriptions (n=47), or has been 116 
reported on aggregated level (n=46, (12)) (figure s2). For such patients, updated and 117 
exhaustive data were collected.  For analysis of serum thyroid function tests, only patients 118 
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whose measurements were performed in the central laboratory of the Erasmus MC were 119 
considered to avoid inter-assay variation. For in-depth clinical and biochemical phenotyping 120 
only those patients were enrolled that either participated in the Triac Trial (12) or in the 121 
named patient program to ensure data had been captured by trained personnel and according 122 
to standard operating procedures. 123 
Ethical considerations 124 
This study conforms to the Declaration of Helsinki, Good Clinical Practice guidelines 125 
and was evaluated and approved by the appropriate local institutional review boards or ethics 126 
committees. However, for the retrospective analysis of existing datasets of patients in routine 127 
clinical care, the majority of centres did not require additional specific institutional review 128 
board approval. For other centres, studies were either ethically approved or the ethics 129 
committee provided a waiver for approval. Informed consent was obtained from the parents 130 
or legal representatives of all enrolled patients, unless the relevant institutional review board 131 
and/or local regulations had authorized the use of anonymised patient data without additional 132 
consent.  133 
Procedures 134 
An overview of study assessments and investigations is provided in figure s1 and in the 135 
Supplementary Methods.  136 
Outcomes 137 
Our primary objective was to analyse the overall survival of patients with MCT8 138 
deficiency and document causes of death. We also compared survival between patients who 139 
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did or did not attain full head control by the age of 1·5 years and between patients who were 140 
or were not already underweight by early childhood (between 1-3 years of age).  141 
Other key objectives were to document neurocognitive function using uniform criteria 142 
and assess their relationship to biological age as a measure of disease progression and 143 
developmental outcome and to describe the occurrence of extra-neurological features.  144 
Statistical analysis 145 
We summarised continuous variables as mean and standard deviation (SD), or median 146 
and range. We established overall survival and compared patients with and without full head 147 
control and cases who were or were not underweight during early childhood with log-rank 148 
analysis. Survival was defined as the age at last date known alive. Hazard ratios were 149 
calculated using Cox regression models. Correlations between biological age and scores on 150 
different neuropsychological assessments were explored using linear regression. For these 151 
analyses, we excluded patients with a n unexpectedly less severe neurocognitive phenotype, 152 
defined as individuals that attained at least two of the following developmental milestones: 153 
talking in simple words, achieving head control, sitting independently, and/or walking with 154 
assistance. Higher developmental attainment in these patients is more likely to be due to the 155 
milder impact of the underlying MCT8 mutation than to the effect of aging. Assumptions for 156 
linear regression analyses were met. All statistical tests were two-sided, and p values of less 157 
than 0·05 were considered statistically significant. Statistical analyses were performed using 158 
GraphPad Prism, version 6 (GraphPad, La Jolla, CA, USA).  159 
Role of funding source 160 
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The funder of the study had no role in study design, data collection, data analysis, data 161 
interpretation, or writing of the report. The corresponding author had full access to all the 162 
data in the study and had final responsibility for the decision to submit for publication. 163 
Results 164 
In 47 centres, 151 patients of 22 different nationalities (8 ethnicities) were enrolled 165 
between October 14th 2014 and January 17th 2020 (figure s1), thereby including 50 percent of 166 
families reported thus far (figure s2). In 106 cases serum thyroid function tests had been 167 
measured in the central laboratory, and 86 had been checked according to standardised 168 
protocols for in-depth phenotyping at a median age of 4·8 years (interquartile range [IQR] 1·9-169 
9·8, range 0·4-66·8) (figure s1).  170 
The demographics and characteristics of the enrolled patients are summarised in table 171 
s1. In the 151 enrolled cases, 73 different underlying MCT8 mutations were identified, of 172 
which 36 had not been reported before (figure s3). A total of 17 mutations were identified in 173 
at least two unrelated families. All 35 missense mutations were located in the transmembrane 174 
helices (figure s4). The median age at diagnosis was 24·0 months (range: 0·0-744·0) (figure 175 
1A), but the median age at onset of first symptoms was 4·0 months (range: 0·0-13·0) (figure 176 
1A). Consequently, the median time to diagnosis was 18·0 months (IQR 7·8-63·0, range 0·0-177 
738·0). The most frequently reported initial concerns that prompted medical evaluation were 178 
gross developmental delay (78·6%), hypotonia (39·8%), feeding problems (8·2%), and poor 179 
weight gain (7·1%) (figure 1B).  180 
32 (21·2%) patients had died and the median age of their demise was 10·5 years (IQR 181 
5·3-18·8, range 1·6-71·0). The main causes of death reported for these patients were 182 
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pulmonary infections (18·8%), sudden death (18·8%), and aspiration pneumonia (9·4%) (figure 183 
1C). In 15 (46·9 %) of 32 deceased subjects the cause of death was unclear and postmortem 184 
examinations had not been performed. The median overall survival was 35·0 years (95% CI 185 
8·3-61·7; figure 1D).  The 10-, 18-, and 60-year survival probabilities were 85% (95% CI 78·0-186 
92·0), 69·8% (58·2-80·3), and 34·8% (10·2-59·3), respectively. Patients not attaining full head 187 
control by the age of 1·5 years had an increased risk for death compared with patients who 188 
did attain head control (HR 3·46, 95% CI 1·76-8·34, p=0·0041; figure 1E). Patients who were 189 
underweight during early childhood (1-3 years of age) had an increased risk for death 190 
compared with patients who were not underweighthad a normal body weight by this age (HR 191 
4·71, 95% CI 1·26-17·58, p=0·021, figure 1F). 192 
The prevalence of specific neurological features in patients included in the in-depth 193 
phenotyped cohort (N=86, median age 4·8 years, IQR 1·9-9·8, range 0·4-66·8) is reported in 194 
table 1 and figure 2, and neurological sequelae are summarized in figure s5 and figure s6. All 195 
patients had moderate-to-severe intellectual disability with a severe delay in motor and 196 
language development (table s2). Only 6 (7·7%) patients achieved independent sitting and 197 
were less severely affected than the other patients (figure 2A). The median score on the Gross 198 
Motor Function Measure (GMFM)-88 (15) did not exceed 10% of the total score that should 199 
be obtained by healthy 4-year old children (figure 2B, table s2). Among 28 subjects that had 200 
been evaluated at a median age of 6·4 years (range 0·4-44·6) with the Bayley Scales of Infant 201 
Development (BSID)-III (16), the median developmental age was well-below 12 months on all 202 
tested sub-domains (figure 2C-G, figure s7B-F, table s2). Similar findings were obtained with 203 
the Vineland Adaptive Behavior Scale (VABS)-II (figure s8, table s2). The scores in any of the 204 
developmental domains did not correlate positively with age (e.g. motor skills: GMFM-88 B=-205 
0·10 (95% CI, -0·29-0·09; p=0.29), BSID-III fine motor skills B= -0·11 (-0·23 - 0·01; p=0.072), and 206 
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BSID-III gross motor skills B= -0·04(-0·11- 0·02; p=0.17); figure 2C-G) and scores of patients 207 
with different age categories were not different (table s2)). 208 
Pregnancy and delivery were unremarkable in the majority of cases, with most infants 209 
having good Apgar scores, normal birth weight at term and head circumference (table 1). At 210 
first presentation, most patients had global hypotonia with a pronounced head-lag on vertical 211 
suspension and upper trunk slipping through. Typically, by the end of the first year, dystonic 212 
posturing of the limbs and neck were noted. Exaggerated deep tendon reflexes were present 213 
in 80·3% (57/71) of cases, and 90·5% (67/74) of patients developed hypertonia in wrists, knees 214 
or heels with age attributed to dystonia and spasticity. Primitive reflexes remained present in 215 
91·1% (51/56) cases, with a positive tonic neck reflex (81·0%) and glabellar sign (80·0%) being 216 
most prevalent, irrespective of patient age. Electro-encephalogram (EEG)-confirmed seizures 217 
were observed in 15 (23·1%) of 65 patients, and mostly involved generalized, absence-like 218 
episodes without a clear motor component.  219 
MRI scans of the brain were available in 13 patients, performed at a median age of 8·0 220 
months (range: 5·0-187·0), with 8 patients having at least one follow-up scan available (table 221 
1, figure s5, table s3). The most consistent finding was a global delay in myelination, evidenced 222 
by diffuse residual hyperintense white matter in specific brain regions on T2-weighted images. 223 
Myelination improved with age, but had not fully normalized in the oldest patient (15 years) 224 
with available data. Most cases showed diffuse cortical and subcortical atrophy with dilatation 225 
of the ventricles, widening of the subarachnoid spaces demonstrated by prominence of the 226 
supra- and infra-tentorial sulci. These neuroradiological findings were supported by 227 
postmortem findings (see supplementary results).  228 
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 Serum thyroid function tests were available in 106 treatment-naïve patients at a 229 
median age of 5·3 years (IQR 2·1-11·0, range 0·4-66·8). Serum TSH concentrations were within 230 
the normal range in 93 (88·6 %) of 105 patients (figure 3A). Serum free and total T4 231 
concentrations were below the age-specific lower limit in 94 (88·7 %) of 106 and 94 (89·5%) 232 
of 105 patients, respectively (figure 3B and figure s9A). Mean serum T3 concentrations 233 
exceeded the age-specific upper limit in 96 (95·1%) of 101 patients (figure 3C), which resulted 234 
in a pronounced increase in the T3/T4 ratio (figure s9B). Reverse T3 (rT3) concentrations were 235 
decreased in 76 (90·5%) of 84 patients (figure s9C), with a concomitant increase in the T3/rT3 236 
ratio (figure s9D). This endocrine signature was present regardless of age (figure s9E-H). In 3 237 
out of 7 subjects TRH-stimulation tests showed an inadequate TSH response. In 7 (87·5%) out 238 
of 8 subjects in whom T4-based neonatal screening results were available, total T4 239 
concentrations were below the 20th percentile (figure 3D), and in 5 out of 8 (60%) below the 240 
10th percentile. By contrast, neonatal TSH concentrations were <15 mU/L in 8/8 (100%) of 241 
patients with available data (figure s9I). Serum total T4 concentrations were significantly less 242 
reduced in patients with less severe versus those with a severe neurocognitive phenotype 243 
(1·05±0·22 vs 0·71±0·18 times the age-specific lower limit of normal, p<0·0001) (figure s10A). 244 
Serum T3 concentrations were not significantly different between these groups (1·46±0·23 vs 245 
1·51±0·44 times the age-specific upper limit of normal, p=0·76)(figure s10B). Consequently, 246 
the T3/T4 ratio, a marker of thyroid hormone metabolism in peripheral tissues, was 247 
significantly lower in patients with a less severe phenotype (1·44±0·40 vs 2·27±0·91 times the 248 
age-specific upper limit of normal, p=0·019)  (figure s10C). 249 
 The main findings of in-depth phenotyping of peripheral clinical features (n=86) are 250 
summarised in table 2 and table s4. Body weight for age showed progressive deterioration 251 
over time, with 59 (71·1%) of 83 patients being severely underweight (<-2SD) (figure 3E, table 252 
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2). 27 (35·5%) of 76 patients were tube fed, although impaired swallowing function was 253 
reported in 55 (71·4%) of 77 patients. Body height for age also deteriorated with age (figure 254 
3F). Delayed sexual maturation was present in 5 (26·3%) patients (figure s11A-D). Among 255 
patients over 8 years of age, bone mineral density (BMD) was below the 5th percentile, but 256 
bone turnover markers were generally within the low-normal range (figure s12A-D). 257 
The mean resting heart rate was 110 (±20)  beats per minute, with 20 (31·3%) of 64 258 
patients exceeding the 90th percentile for age (figure 3G) (17). Systolic blood pressure 259 
exceeded the 90th percentile in 25 (53·2%) of 47 patients whereas the diastolic blood pressure 260 
exceeded the 90th percentile in 17 (36·2%) of 47 patients (figure 3H) (18, 19). Detailed 261 
cardiovascular assessment was available in 50 patients. At the time of evaluation, 47 (94%) of 262 
50 patients reportedly had no cardiovascular abnormalities and were not receiving any 263 
treatment. 3 (6·0%) of 50 patients had second-degree atrioventricular block (Mobitz I: 1; 264 
Mobitz II: 2) and 6 (12·0%) of 50 patients had (incomplete) right bundle branch block. In 265 
addition, corrected QT interval (QTc) was above the 98th percentile in three out of 39 (7·7%) 266 
patients (table 2, figure s13A). Even though most patients were completely immobile, 24h 267 
ambulatory cardiac monitoring showed a high resting heart rate (103±13 beats per minute) 268 
with frequent episodes of tachycardia and premature atrial or ventricular contractions (figure 269 
3I, table s4). One childhood patient had an episode of atrial fibrillation and another had non-270 
sustained ventricular tachycardia (table 2). Cardiac echocardiography studies performed in 26 271 
patients revealed dilated aortic root (>+2SD for age, range 2·0-3·4 SD) in 7 (26·9%) patients, 272 
and relatively small left ventricular wall dimensions (figure s13B).  273 
Serum concentrations of sex hormone binding globulin were elevated in 69 (88·5%) of 274 
78 patients (figure 3J, figure s14). Serum alanine aminotransferase, aspartate 275 
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aminotransferase, and gamma-glutamyl transferase concentrations were mildly elevated in a 276 
substantial proportion of patients (table 2, figure s15D-F), and two patients reportedly had an 277 
episode of hepatic dysfunction following a (viral) infection.  278 
43 (84·3%) of 51 patients had low muscle mass. Creatinine concentrations in serum 279 
were within the low-normal range for age (figure 3K, s14B). Serum creatine kinase 280 
concentrations were mostly low-normal (figure 3L, s14C), with some exceptions in patients 281 
with recent seizures or severe dystonic episodes. Other biochemical tests are shown in table 282 
s4 and figure s15A-O.  283 
Gastroesophageal reflux disease was present in 79·2% (38/48) of patients and this 284 
often required pharmacological intervention. Spontaneous gastrointestinal bleeding was 285 
reported in 2 patients and was the cause of death in one of them. Constipation was present 286 
in 62·3% (37/63) of patients. 29 (69·1%) of 42 patients had recurrent (pulmonary) infections 287 
(table 2). 288 
Discussion 289 
To our knowledge, this international, multicentre, retrospective study reports the 290 
quantitative evaluation of the disease characteristics of MCT8 deficiency, in the largest cohort 291 
of patients with this disorder. We have documented key clinical features together with 292 
biochemical and radiological correlates as well as outcomes in this rare but potentially 293 
treatable condition. Our findings will facilitate accurate diagnosis, guide management, and 294 
inform conduct of future therapeutic intervention trials.  295 
A principal finding is that overall survival of patients with MCT8 deficiency is greatly 296 
diminished, with an overall median life expectancy of 35 years. Stratification of analyses 297 
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revealed that patients who attain full head control are more likely to survive longer than those 298 
who do not. Accordingly, attaining full head control, as a marker of improved 299 
neurodevelopment, could be a relevant endpoint for future therapeutic trials in MCT8 300 
deficiency.  301 
The most common cause of death was pneumonia, caused either by aspiration or by 302 
infections. Aspiration, due to impaired swallowing function, is frequently observed in patients 303 
with MCT8 deficiency, and could be mitigated by tube feeding. However, a substantial number 304 
of patients that exhibited swallowing problems were not tube fed and thus remained at risk 305 
for aspiration. With our study suggesting that being underweight is strongly linked to reduced 306 
survival, tube feeding can prevent adverse clinical sequelae and potentially improve life 307 
expectancy (20). The second major cause of mortality was sudden death. Although its 308 
aetiology remains unclear, available data may suggest a cardiac cause, with the high 309 
prevalence of premature atrial and ventricular contractions, which are uncommon in healthy 310 
individuals especially in childhood (21-25). We also observed non-sustained ventricular 311 
tachycardia and QTc prolongation in some patients, with both considered risk factors for 312 
sudden cardiac death. Moreover, a substantial proportion of patients exhibited systolic 313 
hypertension and/or tachycardia and had several echocardiographic and electrophysiological 314 
cardiac changes that have been linked to these traits. As the vast majority (94·0%) of patients 315 
reportedly had no history of cardiac problems, these cardiovascular abnormalities likely 316 
remain clinically undiagnosed in this population. This observation calls for inclusion of 317 
cardiovascular assessment in the management of this disorder. With loss of body weight and 318 
many cardiovascular abnormalities being attributable to chronic thyrotoxicosis, reduction in 319 
circulating T3 concentrations in patients could represent effective treatment for these aspects 320 
of the disorder. Indeed, in a recent clinical trial, treatment with the thyroid hormone analogue 321 
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Triac efficiently reduced serum T3 concentrations and improved key clinical features such as 322 
loss of body weight and reversal of abnormal cardiovascular parameters in MCT8 deficiency 323 
(12).  324 
The current study also identified several other clinical features that require treatment 325 
or close follow-up, of which gastro-esophageal reflux disease, scoliosis, hip luxation, and 326 
constipation have the highest prevalence. The presence of mildly elevated aminotransferases 327 
and the occurrence of transient hepatic failure in at least three reported cases following a viral 328 
infection [this report and (11)], suggests that drugs with hepatotoxic side effects (e.g. anti-329 
epileptic drugs as frequently used in this population) should be used with extra caution. 330 
Our comprehensive documentation of neurological sequelae in patients with MCT8 331 
deficiency revealed that the combination of global hypotonia, hypertonia due to dystonia and 332 
spasticity and persistence of primitive reflexes was present in up to 90% of patients. Delayed 333 
myelination on MRI was consistent with other studies (14, 26, 27). Taken together, these 334 
clinical and neuroimaging characteristics may facilitate early diagnosis of MCT8 deficiency and 335 
in discriminating this entity from other neurodevelopmental disorders.  336 
Our study highlights major delay in diagnosis of this disorder, with a minority of cases 337 
being identified in the first year of life. This is mainly attributable to the non-specific initial 338 
clinical features with lack of awareness of the specific characteristics of this disorder among 339 
clinicians. Having documented that circulating T3 concentrations are elevated in patients 340 
below one year of age, the combination of clinical and radiological features with measurement 341 
of serum T3 concentrations may constitute a key clue for early diagnosis. The low T4 342 
concentrations measured in patients with MCT8 deficiency in the neonatal screening indicates 343 
the potential to diagnose MCT8 deficiency in newborns. This may engender debate on 344 
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whether modification of the current neonatal screening strategy is warranted. The importance 345 
of early diagnosis is supported by preclinical studies in which Triac completely prevented 346 
abnormal neurological development in animal models of MCT8 deficiency when administrated 347 
at birth (28). A future phase 2 clinical trial will investigate the effects of Triac on 348 
neurodevelopment, with treatment being commenced at a very young age (NCT02396459).  349 
This study has limitations inherent to its retrospective design. In general, such study 350 
design is prone to collection of an incomplete dataset, possibly resulting in selection bias. 351 
Indeed, most assessments could not be carried out in all patients, resulting in missing data. 352 
The cause of this mostly reflected disease characteristics, such as a poor clinical condition of 353 
patients, their inability to follow instructions and dystonic posturing that hampered 354 
investigations for which patients needed proper positioning. Therefore, some conclusions are 355 
based on a limited number of observations. Yet, calculated prevalence rates for many clinical 356 
features were similar to those observed in smaller cohort studies and through analysis of 357 
existing literature (14). It was also not possible to obtain uniform long-term follow-up data. 358 
However, MCT8 deficiency is a rare disorder with surviving patients being located throughout 359 
the world such that retrospective analysis of available clinical data was the most suitable way 360 
of increasing our understanding of this disorder. In the majority of cases data had been 361 
collected uniformly during baseline assessment of patients whether participating in the Triac 362 
Trial or in named patient treatment programs, providing an unique opportunity for systematic 363 
cross-sectional evaluation of key clinical outcomes. Should MCT8 deficiency result in an 364 
increased rate of miscarriage this will likely remain unascertained, resulting in survivor bias.  365 
Although selection bias cannot be excluded, probably because not all newly diagnosed cases 366 
are brought to our attention and patients who die before the diagnosis has been established 367 
are being missed, our study included a substantial proportion of currently diagnosed patients. 368 
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With advent of Triac as possible disease-modifying therapy, a future, prospective cohort study 369 
of the natural history of the disorder is unlikely to be possible. 370 
In summary, this study provides a comprehensive and structured in-depth 371 
characterisation of the phenotype of MCT8 deficiency. The current study first reports poor 372 
survival in this disorder, with 30% of patients dying in childhood. Having identified pulmonary 373 
infection and sudden death (our data suggests cardiac arrhythmia as underlying basis) as the 374 
major causes of mortality, timely intervention with Triac therapy may ameliorate the poor 375 
prognosis in this disease. Furthermore, our finding that survival is particularly poor in patients 376 
with impaired neurological development (head control) or who are underweight, provides a 377 
basis for therapeutic intervention targeted at this subgroup. Our findings underscore the need 378 
for a multidisciplinary approach in the management and follow-up of patients with MCT8 379 
deficiency. In addition, our observations represent an unique, quantitative dataset of the 380 
characteristics of this disorder which may serve as a historical control for future interventional 381 
studies in this rare disorder, for which a biological control group is often deemed not feasible. 382 
Accordingly, we suggest that this study enhances our understanding of the clinical sequelae 383 
and longterm outcome of MCT8 deficiency and also facilitates the diagnosis and management 384 
of this disorder. 385 
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Legends to the Figures 516 
Figure 1 – Panel A graphically presents the mean ± SEM (black lines) age at onset of symptoms 517 
and the age at time of diagnosis. Grey dots represent measurements in individual patients. 518 
Panel B shows the most commonly reported features that prompted parents to seek medical 519 
attention. Panel C shows the causes of death in patient with MCT8 deficiency based on the 520 
available information derived from the 32 patients in our cohort who died at a median age of 521 
10·5 years (IQR 5·3-18·8, range 1·6-71·0). HR: hazard ratio, calculated using Cox regression 522 
models. Panel D shows the overall survival based on age at last follow-up (Kaplan-Meier 523 
estimates). Panel E shows the Kaplan-Meier estimates of MCT8-specific survival in patients 524 
who attained head control (red line) by the age of 1·5 years versus those who did not (blue 525 
line) and panel F those in patients with underweight (blue line) versus without normal body 526 
weight (red line) underweight in early childhood (1-3 years of age). Underweight was defined 527 
as a body weight for age z score <-2SDs (or below the fifth percentile), following the definition 528 
of the World Health Organization. Please note, since potential confounding factors could not 529 
be accounted for, a causal relationship on survival cannot be inferred from the applied 530 
stratification variables. 531 
Figure 2 – Panel A shows the prevalence of clinical, radiological and developmental key 532 
features in MCT8 deficiency. Bars indicate the proportion of patients presenting the indicated 533 
feature at first presentation. Panel B represents the gross motor function development in 534 
patients with MCT8 deficiency measured by the Gross Motor Function Measure (GMFM)-88 535 
(15). A 100% score indicates the level of development that is achieved by a healthy 4-year old 536 
child. Panel C shows cognition, panel D receptive language, panel E expressive language, panel 537 
F fine motor skills and panel G gross motor skills, measured by the respective sub-domains of 538 
the Bayley Scales of Infant Development (BSID)-III (16). Scores are expressed as developmental 539 
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age in months. In panels B-G, the left figures indicate measurements in individual patients 540 
(blue dots) and black lines indicate the median score and IQR from all patients with available 541 
data. The right figures show the relation between the neurodevelopmental scores versus the 542 
chronological age using linear regression. A few, predominantly older patients , with an 543 
unexpectedly less severe neurocognitive phenotype (defined as having at least 2 of the 544 
following abilities: talk in simple words, attain head control, independent sitting, and/or 545 
walking with assistance) were excluded from the regression analysis (n=4 for GMFM-88 in 546 
panel B, and n=1 for BSID-III in panel C-G), which focused on individuals with classical sequelae 547 
of severe MCT8 deficiency (indicated with grey dashed lines in the left figure of each panel ; 548 
n=40 for GMFM-88 in panel A, and n=27 for BSID-III in panel C-G) Linear regression was used 549 
to plot the trend (blue solid lines) and the 95% confidence intervals (blue dotted lines). Besides 550 
age, no other factors were considered in the models. Patients harboring the same genetic 551 
mutation are displayed in the same color: p.F230del (green), c.651-652+20del (blue), G564R 552 
(purple), p.A565fs566X V566X (pink), and R271H (orange). Unique mutations are colored in 553 
grey. 554 
Figure 3 – Mean ± SEM (black lines) serum concentrations of thyroid stimulating hormone 555 
(TSH) (n=106) (panel A) and free T4 (n=106) (panel B). Blue dots represent measurements in 556 
individual patients and grey areas the normal range. Panel C presents the serum total T3 557 
concentrations versus age (n=101). Panel D shows the available results on total T4 558 
measurements during neonatal screening expressed in SDs (n=8). See figure s9I for TSH 559 
measurements during neonatal screening. Panel E shows the natural course of bodyweight 560 
change in patients with MCT8 deficiency. Blue dots represent available historical bodyweight 561 
measurements (n=300) in 86 untreated patients. Non-linear (third order) polynomial 562 
regression was used to plot the trend with its 95% error band. Similarly, panel F shows the 563 
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natural course of body height. Accurate measurement of body height can be hampered by 564 
muscle contractions and involuntary movements. Panel G shows the resting heart rate by age 565 
(n=64). Normal range in healthy children is derived from (17). Panel H shows the mean ± SEM 566 
diastolic and systolic blood pressure (n=47). The orange line represents the threshold for 567 
classification as elevated blood pressure and the red line the threshold of hypertension, as 568 
defined by the guidelines from the American Academy of Pediatrics (18) and the American 569 
College of Cardiology and American Heart Association (19). Panel I shows the mean ± SEM 570 
(black lines) occurrence of indicated features during 24h cardiac monitoring in 45 individuals. 571 
Serum concentration of sex hormone binding globulin (SHBG) (n=78) (panel J), creatinine 572 
(n=79) (panel K), and creatine kinase (n=79) (panel L) are expressed relative to the age-specific 573 
lower (panel K) or upper (panel J and L) limit of the normal range. Abbreviations: TSH, thyroid 574 
stimulating hormone; T4, thyroxine; T3, triiodothyronine; PACs, premature atrial contractions; 575 
PVCs premature ventricular contractions; CK, creatine kinase; SHBG, sex hormone binding 576 
globulin; LL, lower limit; UL, upper limit. The absolute mean values of all parameters are 577 
summarized in table s4.  578 
 579 
 580 Formatted: Normal
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Table 1. In depth phenotyping of neurodevelopmental features 
 N=86 
Age at assessment (years) 4·8 (0·44-66·8) 
Perinatal features  
 Pregnancy duration (weeks) 40·0 (32·0-42·3) 
 Apgar scores >8 after 5 min (n=16) 15 (93·8) 
 Term birth weight (grams) 3584 (±517) 
 Microcephaly (<3th centile) at birth (n=11) 2 (18·2) 
Neurological examination   
 Hypotonia (n=72) 72 (100%) 
 Primitive reflexes (>1 present) (n=56) 51 (91·1%) 
    Tonic neck reflex (n=21) 17 (81·0%) 
    Glabellar sign (n=55) 44 (80·0%) 
    Startle response (n=25) 17 (68·0%) 
 Scoliosis (>8 years) (n=17) 15 (88·2%) 
 Muscle hypoplasia (n=51) 43 (84·3%) 
 Dystonia (n=69) 57 (82·6%) 
 Spasticity (n=71) 57 (80·3%) 
 Urinary / faecal incontinence (>4 years) (n=41) 33 (80·5%) 
 Feeding problems (n=77) 55 (71·4%) 
 Hip dislocation (>8 years, n=15) 10 (66·7%) 
 Plantar extension response (Babinski sign, n=57) 38 (66·7%) 
 Delayed evoked potentials (<6 months, n=6)* 3 (50·0%) 
 Sleep problems (n=51) 20 (39·2%) 
 Tube feeding (n=76) 27 (35·5%) 
 Strabismus (n=54) 19 (35·2%) 
 Microcephaly (<3th centile) (n=59) 19 (32·2%) 
 Nystagmus (n=49) 13 (26·5%) 
 Extrapyramidal signs (other) (n=28) 7 (25·0%) 
 Seizures (EEG proven) (n=65) 15 (23·1%) 
 Apneusis (n=32) 7 (21·9%) 
 Abnormal hearing (n=44) 1 (2·3%) 
 Delayed evoked potentials (>1 year, n=3) 0 (0·0%) 
Development  
 Head control (n=77) 19 (24·7%) 
 Speech (at least 1 word) (n=76) 5 (6·6%) 
 Independent sitting (n=78) 6 (7·7%) 
 Independent walking (n=77) 4 (5·2%) 
MRI/MRS characteristics*  
 Normal global anatomy (n=13) 13 (100%) 
 Delayed myelination (n=13) 13 (100%) 
 Reduced cerebral white matter volume (n=13) 13 (100%) 
 Periventricular white matter lesions (n=10) 10 (100%) 
 Prominent supratentorial ventricular system (n=13) 13 (100%) 
 Prominent peripheral liquor spaces (n=13) 13 (100%) 
 Low NAA peak (n=7) 6 (85·7%) 
 High choline peak (n=7) 6 (85·7%) 
Data are median (range), n (%), or mean (±SD). Systematic deep 
phenotyping of neurological phenotype in 86 eligible patients. Median age 
at last available MRI scan: 18·0 months, range 5·0-187·0); MRS was 
available in 7 cases. Details are provided in table s2. 
* In particular the brainstem-evoked response audiometry was abnormal 






Table 2. In depth phenotyping of peripheral features 
Characteristic N=106 
Serum thyroid function tests  
Age at measurement (years) 5·3 (0·4-66·8) 
Elevated T3 concentrations (n=101) 96 (95·1%) 
Reduced free T4 concentrations (n=106) 94 (88·7%) 
Deep phenotyping N=86 
Age at assessment (years) 4·8 (0·44-66·8) 
Biochemical measurements *  
 Elevated sex hormone binding globulin (n=78) 69 (88·5%) 
 Elevated alanine aminotransferase (n=65) 30 (46·2%) 
 Reduced creatinine (n=79) 22 (27·8%) 
 Elevated lactate (n=11) 3 (27·3%) 
 Reduced total cholesterol (n=65) 12 (18·5%) 
 Elevated aspartate aminotransferase (n=56) 11 (19·6%) 
 Elevated creatine kinase (n=79) 3 (3·8%) 
Clinical features  
 Low bone mineral density (>8 years, n=5) 5 (100%) 
 Hypotrophic musculature (n=51) 43 (84·3%) 
 Gastro-esophageal reflux disease (n=48) 38 (79·2%) 
 Premature atrial complexes (n=45) 34 (75·6%) 
 Recurrent (pulmonary) infections (n=42) 29 (69·0%) 
 Underweight (<-2 SD, n=83) 59 (71·1%) 
 Constipation (n=63) 37 (58·7%) 
 Elevated systolic blood pressure ¶  (n=47) 25 (53·2%) 
 Increased perspiration (n=60) 29 (48·3%) 
 Short stature (<-2 SD, n=67) 27 (40·3%) 
 Premature ventricular complexes (n=45) 19 (42·2%) 
 Tachycardia in rest † (n=64) 20 (31·3%) 
 Aortic root dilatation (n=26) 7 (26·9%) 
 Elevated diastolic blood pressure ¶ (n=47) 17 (36·2%) 
 Delayed sexual maturation (>8 years, n=19) 5 (26·3%) 
 Cardiac conduction abnormalities ‡ (n=50) 9 (18·0%)  
 Cryptorchidism (n=49) 9 (18·4%) 
 Prolonged QTc interval (39) 3 (7·7%) 
 Supraventricular tachycardia (n=48) 2 (4·2%) 
 (Non-sustained) ventricular tachycardia (n=48) 2 (4·2%) 
 Atrial fibrillation (n=48) 1 (2·1%) 
Data are median (range), or n (%). Systematic deep phenotyping of the 
peripheral phenotype. Please note that most parameters have not been 
captured in all patients. All absolute and relative values are provided in 
table s4.  
* Reduced and elevated indicated concentrations below or above the 
normal range (2.5-97.5 centile in the healthy population). 
 † Tachycardia was defined as a resting heart rate above the 90th 
percentile for the corresponding age, with cut-offs described by 
Fleming and colleagues (17). 
‡Three out of 50 patients (5·5%) had a second degree atrioventricular 
block (Mobitz I:1; Mobitz II:2) and 6 out of 50 patients (12·0%) had an 
(incomplete) right bundle branch block and 1 patient (2·0%) had a left 
posterior hemiblock. 
¶ Elevated systolic and diastolic blood pressure were defined using the 
guidelines from the American Academy of Pediatrics (18) and the 
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